AS
NBIX icon

AM Squared’s Neurocrine Biosciences NBIX Stock Holding History

AM Squared’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$104K Buy
+900
New +$123K 0.23% 30

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AM Squared's NBIX Position: Q3 2024 in Review

AM Squared opened a new position in Neurocrine Biosciences (NBIX) in Q3 2024: 900 shares worth $104K. The stake represents 0.23% of the portfolio and ranks #30 among its holdings.

575 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • AM Squared held 900 shares of Neurocrine Biosciences worth $104K as of Q3 2024.
  • Neurocrine Biosciences was a new AM Squared position in Q3 2024.
  • Neurocrine Biosciences made up 0.23% of AM Squared's portfolio in Q3 2024, its #30 holding.
  • 575 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on AM Squared's 13F filing for Q3 2024, filed 7 Nov 2024.